药明康德：受托人完成25亿港元H股股票购买 智通财经6月30日电，药明康德(603259.SH)公告称，公司受托人已完成《2025年H股奖励信托计划》项 下合计25亿港元的H股股票购买，该等股票将作为基本授予条件及附加授予条件项下授予奖励股票的来 源。 ...

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | 於下列日期開始時的結存(註1) | 2025年6月27日 | | 2,485,141 ...

Core Insights - The Hong Kong Innovation Drug Index (931787) has shown a positive performance, with significant increases in constituent stocks such as Zai Lab (11.01%) and Cloudmed (9.27%) [1] - The Hong Kong Innovation Drug ETF (513120) has experienced active trading, with a turnover of 33.61% and a total transaction volume of 4.472 billion [1] - The ETF has seen a continuous net inflow of funds over the past 14 days, totaling 3.159 billion [1][2] Market Performance - As of June 27, the Hong Kong Innovation Drug ETF has achieved a net value increase of 86.07% over the past year, ranking 1st out of 120 in QDII equity funds [2] - The ETF's highest monthly return since inception was 23.82%, with the longest consecutive monthly gain being 4 months and a maximum cumulative increase of 44.08% [2] - The average monthly return during the rising months is 7.59% [2] Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the Hong Kong Innovation Drug ETF is 32.62, which is below the 83.82% historical level over the past five years, indicating a low valuation [2] - The ETF closely tracks the Hong Kong Innovation Drug Index, which includes up to 50 listed companies primarily engaged in innovative drug research and development [2] Industry Developments - The top ten weighted stocks in the Hong Kong Innovation Drug Index account for 71.99% of the index, with notable companies including Innovent Biologics and BeiGene [3] - The approval of a new drug by the National Medical Products Administration (NMPA) for long-term weight control in adults marks a significant development in the industry [3] - Recent reports suggest that China's innovative drug sector is becoming a global supplier of innovative therapies, driven by high efficiency and low-cost development advantages [4] Investment Opportunities - The Hong Kong Innovation Drug ETF provides exposure to leading companies in the innovative drug sector, such as Innovent Biologics and CanSino Biologics [4] - The ETF supports T+0 trading, enhancing liquidity and allowing investors to conduct multiple transactions within a trading day [4]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

Core Viewpoint - WuXi AppTec (603259.SH/02359) has initiated a share repurchase plan amounting to RMB 1 billion, reflecting the company's commitment to enhancing shareholder value and confidence in its operational performance [1][2][3] Group 1: Share Repurchase Details - The company plans to repurchase approximately 11.02 million shares, representing 0.3817% of its total share capital, within a 12-month period starting from April 29 [1] - On June 26, the company commenced the repurchase by acquiring 302,500 A-shares at a maximum price of RMB 67.36 per share and a minimum price of RMB 65.54 per share, utilizing around RMB 20 million [1][2] Group 2: Financial Performance and Shareholder Returns - WuXi AppTec completed its second share repurchase plan of RMB 1 billion by June 20, having acquired 15.7754 million shares, demonstrating a swift execution of its financial strategies [2][3] - The total shareholder return announced and implemented by the company in 2025 is estimated to exceed RMB 6 billion, including cash dividends and share repurchase plans [3] - Since its IPO in 2018, the company has returned approximately RMB 14 billion in cash dividends to investors, showcasing its commitment to rewarding long-term shareholders despite various economic challenges [3] Group 3: Operational Performance - The company's Q1 2025 report indicates a return to double-digit growth, with revenue reaching RMB 9.655 billion, a year-on-year increase of 21%, and an adjusted net profit of RMB 2.68 billion, reflecting a 40% growth [3]

Group 1 - The core viewpoint of the articles highlights WuXi AppTec's commitment to shareholder value through significant share buybacks and dividends, demonstrating a strong focus on market capitalization management [1][2]. - WuXi AppTec completed its second share buyback of the year on June 20, amounting to approximately 1 billion yuan, with 15.7754 million shares being canceled on June 24 [1]. - The company has a tradition of returning value to shareholders, having executed three rounds of share buybacks totaling 3 billion yuan in 2024 alone [1]. Group 2 - Since the introduction of the new "National Nine Articles" in April 2024, share buybacks have become a key focus for A-share listed companies, with a 179% increase in buyback scale for market capitalization management in 2025 compared to the same period in 2024 [2]. - WuXi AppTec has conducted four share buybacks in the past 16 months, all of which have been fully canceled, reflecting its commitment to enhancing shareholder returns [2]. - The company's stock performance has significantly outpaced broader market indices, with A-share prices increasing sevenfold and H-share prices tripling since its listing [2]. Group 3 - In response to complex geopolitical environments, WuXi AppTec plans to invest 7-8 billion yuan in building bases in China, the United States, Europe, and Singapore, further solidifying its global leadership in CRDMO services [4]. - The company's strategy of "internal growth + external expansion" provides a rare certainty in a volatile market, supporting sustained shareholder returns with solid performance [4].

Individual Company News - Xiaomi Group (01810.HK) officially launched its first SUV, the Xiaomi YU7, with a starting price of 253,500 yuan, achieving over 289,000 pre-orders within one hour [1] - WanGuo Data (09698.HK) has received approval from the China Securities Regulatory Commission and the Shanghai Stock Exchange for the registration and initial public offering of its closed-end infrastructure securities investment fund [1] - China Biologic Products (01177.HK) has included a new indication for its LM-108 "CCR8 monoclonal antibody" in the breakthrough therapy designation program [1] - China Life Insurance (02628.HK) plans to invest 1.2 billion yuan to establish a partnership for investing in nuclear power enterprises [1] - New Special Energy (01799.HK) subsidiary Fengsheng Power received a 500 million yuan capital increase from ICBC Financial, diluting its stake to 55.62% [1] - WuXi AppTec (02359.HK) was increased by Computershare Hong Kong Trustees Limited by 1.1786 million shares at approximately 76.70 HKD per share [1] - Bosideng (03998.HK) reported a profit attributable to shareholders of 3.514 billion yuan for the year ending March 31, 2025, representing a year-on-year increase of 14.31% [1] Strategic Review - Hong Kong Travel (00308.HK) board is continuously conducting periodic research and strategic reviews of the company's business layout and portfolio, with no guarantees that the review process will lead to any announcements or completed transactions [2]

Core Insights - WuXi AppTec's Nantong site has been awarded the Popular Choice Winner in the "Factory & Warehouse" category at the 2025 Architizer A+Awards, highlighting the company's commitment to innovative and human-centric workplaces [1][2] - The Nantong site is part of WuXi AppTec's CRDMO platform, providing comprehensive chemistry, biology, and testing solutions to global customers, designed to enhance operational efficiency and foster collaboration [3][4] - The company emphasizes integrating technology, environmental sustainability, and community engagement in its operations, with other sites like Couvet in Switzerland and Munich in Germany showcasing advanced energy efficiency and sustainable construction [4] Company Overview - WuXi AppTec operates globally across Asia, Europe, and North America, offering a wide range of R&D and manufacturing services to the pharmaceutical and life sciences industries [5] - The company aims to improve healthcare product development through cost-effective and efficient solutions, serving around 6,000 customers from over 30 countries [5] - WuXi AppTec has received an AA ESG rating from MSCI for four consecutive years, reflecting its commitment to sustainability and social responsibility [5]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-043 无锡药明康德新药开发股份有限公司 关于 2025 年第一次以集中竞价交易方式首次回购公司股份 暨股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/3/18 □用于转换公司可转债 □为维护公司价值及股东权益 | 累计已回购股数 | 302,500股 | | --- | --- | | 累计已回购股数占总股本比例 | 0.0105% | | 累计已回购金额 | 20,008,386.00元 | | 实际回购价格区间 | 65.54元/股~67.36元/股 | 一、 回购股份的基本情况 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开第三届董事会第十七次会议暨 2024 年年度董事会，并于 2025 年 4 月 29 日 召开 2024 年年度股东大会，审议通过《关于 2025 年以集中竞价交易方式回购公 司 A 股股份的议案》，同意使用自有资金和自筹资金 ...